Federal Trade Commission enforcement under a proposed update to its Negative Option Rule for marketers extends “far beyond” the targeted type of abuses and could be used to impose civil penalties for product efficacy claims, says the commission’s recently retired Republican appointee.
In Parting FTC Shot, Wilson Pins Negative Option Proposal To Democrat Majority Overreach
“The rule would capture misrepresentations regarding the underlying product or service wholly unrelated to the negative option feature,” says Christine Wilson in dissenting statement on FTC’s notice of proposed rulemaking.
More from Archive
More from HBW Insight
• By
Swiss firm reports highest revenues in its history as restructure pays off for its pharma and cosmetics businesses in 2024.
• By
Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.
• By
The departure data emerged along with a Health and Human Services Department memo describing conceptual plans to consolidate and restructure offices at the FDA and other agencies.